Cancer Research

An anti-cancer drug in short supply can now be made by microbes

September 1, 2022

Saccharomyces cerevisiae, also known as brewer’s yeast, has been dyed blue to be seen under a microscope.

Saccharomyces cerevisiae, also known as brewer’s yeast, is seen under a microscope. This species is used around the world to...

Vicinitas Therapeutics Launches to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

July 28, 2022

Logo for Vicinitas Therapeutics

Berkeley, CA

It was announced today that Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel...

Novartis and UC Berkeley Extend Alliance to tackle undruggable diseases

July 28, 2022

Illustration of DUBTAC target

Illustration of DUBTAC in action against a target. (Courtesy Nomura Lab)

Novartis-Berkeley Translational Chemical Biology Institute combines Novartis expertise in chemical biology and medicinal chemistry with Berkeley’s expertise in covalent chemoproteomics and chemistry methodologies Research collaboration aims to unlock...

Scientists find trigger that sets off metastasis in pancreatic cancer

July 5, 2022

Illustration of Healthy pancreas (left) and metastatic tumors on the liver (right)

Scientists have found that cancers in the pancreas (left) readily metastasize because these tumors suppress levels of an enzyme, MSRA, that pulls oxygen atoms off amino acids called methionine. As MSRA levels decrease, methionines on...

An expert on 'undruggable' targets tackles the coronavirus

October 5, 2020

Dan Nomura

Nomura in his lab at UC Berkeley. Photo: Elena Zhukova

Throughout the grim reality of a global pandemic that has disrupted normal life for months, one persistent bright spot has been the robust response of the biomedical research community. The battle to develop vaccines and drugs to fight the SARS-CoV-2 virus and COVID-19, the disease which it causes,...

How scientists shot down cancer’s ‘Death Star’

February 5, 2021

lung cancer cell

A colored scanning electron micrograph of a cell of a common type of lung cancer, called non-small cell cancer. A new drug targets the mutated protein that leads to uncontrolled growth. Credit Steve Gschmeissner/Science Source

After 40 years of effort, researchers have finally succeeded in switching off...

Megaphages harbor mini-Cas proteins ideal for gene editing

July 20, 2020

Illustration of a megaphage injecting its DNA into a gene

The DNA-cutting proteins central to CRISPR-Cas9 and related gene-editing tools originally came from bacteria, but a newfound variety of Cas proteins apparently evolved in viruses that infect bacteria. The new Cas proteins were found in the largest known bacteria-infecting viruses, called bacteriophages, and are the most compact working Cas variants yet discovered — half the size of today’s workhorse, Cas9.

Skin cancer mystery revealed in Yin and Yang protein

December 29, 2019

research announcement about B-Raf V600E

Researchers in the UC Berkeley lab of John Kuriyan, Chancellor's Professor at the University of California, Berkeley in the departments of Molecular and Cell Biology and Chemistry, have utilized powerful NSF funded supercomputers at the University of Texas Advanced Computing Center and the Pittsburgh Supercomputing Center to uncover the mechanism that activates cell mutations found in about 50 percent of melanomas.

Two startups founded by Chemistry faculty to watch

November 18, 2019

UC Berkeley startups to watch

Even the hippest chemist doesn’t know how many potentially world-changing chemistry start-ups are out there. As we at C&EN present our fifth class of 10 Start-Ups to Watch (two companies are founded by UC Berkeley faculty and alum), we can confirm that there are definitely hundreds, and perhaps thousands. That makes the job of picking just 10 a challenge—though an inspiring one. This year’s choices were selected after vigorous debate by our writers and editors. We made our own lists based on our day-to-day reporting and scoured the hundreds of firms nominated by readers and advisers from around the world. We picked winners for their groundbreaking chemistry as well as the importance of the problems they are tackling.

Alumna Margaret Chu-Moyer in the news

November 12, 2019

Margaret Chu-Moyer

When Chu-Moyer was tapped to head up the research and chemistry groups across Amgen’s three U.S. R&D sites in 2014, she knew she would have to make some changes for the company to succeed in bringing a KRAS inhibitor into clinical trials, along with other novel treatments for cancer, cardiovascular disease and neurological disorders. For one, she needed to improve the collaboration between scientists who had different areas of expertise—and who lived and worked in different zip codes.